- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel, paroxetine / Generic mfg.
Clinical, P1 data, PK/PD data, Journal: Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial. (Pubmed Central) - Mar 1, 2025
The pharmacokinetic and pharmacodynamic interactions indicate that no dose adjustment of LSD seems necessary in the presence of an SSRI that inhibits CYP2D6. For SSRIs that do not relevantly inhibit CYP2D6, a dose increase of LSD might be appropriate, but due to lacking data and potential other pharmacokinetic interactions with these compounds, no definitive dose recommendation can be made.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Journal: Treatment of neuropathic pain with repeated low-dose MDMA: a case report. (Pubmed Central) - Feb 18, 2025
A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium to high doses of lysergic acid diethylamide (LSD) and high doses and microdoses of methylenedioxymethamphetamine (MDMA)...This case documents benefits of low doses of MDMA for the treatment of a pain disorder. Further research is needed on effects of MDMA on pain.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion date, Trial primary completion date: A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) (clinicaltrials.gov) - Jan 28, 2025
P3, N=200, Recruiting,
Further research is needed on effects of MDMA on pain. Trial completion date: Jun 2027 --> Nov 2026 | Trial primary completion date: Dec 2026 --> May 2026
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Clinical, Journal: Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response. (Pubmed Central) - Sep 21, 2024
This study compared the subjective effects of lysergic acid diethylamide (LSD) and psilocybin between patients undergoing PAT and healthy volunteers...Patients may experience more challenging psychedelic effects and reduced ego dissolution. Hourly assessment of drug effects may predict clinical outcomes better than retrospectively assessed mystical experiences, and the impact of relaxation during PAT should be investigated further.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Review, Journal: Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions. (Pubmed Central) - Jul 28, 2024
Psychedelics like LSD (Lysergic acid diethylamide) and psilocybin are known to modulate perceptual modalities due to the activation of mostly serotonin receptors in specific cortical (e.g., visual cortex) and subcortical (e.g., thalamus) regions of the brain...This paper presents an understanding of how the retinofugal pathway communicates and modulates visual information in psychedelic and clinical conditions. Therefore, we elucidate a new theory of psychedelic modulation in the retinofugal pathway.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
LSD-Assisted Therapy in Patients with Anxiety: A Prospective 12-Month Follow-Up (Griffin Hall) - Apr 14, 2024 - Abstract #SOBP2024SOBP_811;
Similar effects were observed for comorbid depression with change from baseline BDI scores of -8.1 (-13.2, -3.1), d=0.71, p<0.01, and -8.9 (-12.9, -4.9), d=1.21, p<0.01, for the LSD-first and placebo-first groups, respectively. Personality trait neuroticism decreased (p<0.0001) and trait extraversion increased (p<0.01) compared with study inclusion.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial initiation date: LPC: Lysergic Acid Diethylamide (LSD) in Palliative Care (clinicaltrials.gov) - Mar 12, 2024
P2, N=60, Recruiting,
Active, not recruiting --> Completed Initiation date: Sep 2023 --> Mar 2024
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion date, Trial primary completion date: Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache (clinicaltrials.gov) - Feb 15, 2024
P2, N=30, Recruiting,
Initiation date: Sep 2023 --> Mar 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion, Trial completion date, Trial primary completion date: LSD-Bio: LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects (clinicaltrials.gov) - Feb 13, 2024
P1, N=20, Completed,
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024 Recruiting --> Completed | Trial completion date: Mar 2023 --> Oct 2023 | Trial primary completion date: Mar 2023 --> Oct 2023
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion, Phase classification: Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial (clinicaltrials.gov) - Jan 17, 2024
P2, N=53, Completed,
Recruiting --> Completed | Trial completion date: Mar 2023 --> Oct 2023 | Trial primary completion date: Mar 2023 --> Oct 2023 Active, not recruiting --> Completed | Phase classification: P2a --> P2
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Review, Journal, Metabolomic study: Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans. (Pubmed Central) - Dec 7, 2023
This review presents the state of the art of metabolic and metabolomic studies after lysergic acid diethylamide (LSD), mescaline, N,N-dimethyltryptamine (DMT) and ?-carboline alkaloids (ayahuasca brew), 5-methoxy-DMT and psilocybin administrations in humans...Thus, whereas the main metabolites for classical psychedelics have been robustly established, the main metabolic alterations induced by psychedelics need to be explored. The integration of metabolomics and pharmacokinetics for investigating the molecular interaction between psychedelics and multiple targets may open new avenues in understanding the therapeutic role of psychedelics.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Journal: The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. (Pubmed Central) - Oct 31, 2023
Data from 239 PES measurements (140 healthy participants) from six studies with moderate to high doses of lysergic acid diethylamide and/or psilocybin were included...The study yields a new validated 6-factor structure for extended mystical experience (MEQ40: MEQ30 + Paradoxicality + Connectedness) and covers psychedelic experience as a whole more comprehensively than has hitherto been possible within a single questionnaire (PES48). The entire PES (PES100) can also be used for further future psychedelic-psychometric research.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment closed: Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial (clinicaltrials.gov) - Oct 26, 2023
P2a, N=53, Active, not recruiting,
The entire PES (PES100) can also be used for further future psychedelic-psychometric research. Recruiting --> Active, not recruiting
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment open: LPC: Lysergic Acid Diethylamide (LSD) in Palliative Care (clinicaltrials.gov) - Aug 14, 2023
P2, N=60, Recruiting,
LSD is extensively metabolized and shows dose-proportional urinary recovery. Not yet recruiting --> Recruiting
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Journal: The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. (Pubmed Central) - Jun 16, 2023
Together, these findings suggests that LSD perturbs the Excitation/Inhibition balance of the brain. Notably, whole-brain EC did not only provide additional mechanistic insight into the effects of LSD on the Excitation/Inhibition balance of the brain, but EC also correlated with global subjective effects of LSD and discriminated experimental conditions in a machine learning-based analysis with high accuracy (91.11%), highlighting the potential of using whole-brain EC to decode or predict subjective effects of LSD in the future.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel, N, N-dimethyltryptamine (DMT IV) / Mindmed
Journal: Classic psychedelics do not affect T cell and monocyte immune responses. (Pubmed Central) - Feb 7, 2023
We concluded that LSD, psilocin, DMT, or mescaline did not directly stimulate the proliferation or cytokine secretion of primary human T lymphocytes or stimulate NF-κB induction of monocytes. Our findings support the future safe use of classic psychedelics in assisted psychotherapy in patients with life-threatening diseases where immune suppression and diminished immune function would be detrimental.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion, Trial primary completion date: LSD Therapy for Persons Suffering From Major Depression (clinicaltrials.gov) - Jan 26, 2023
P2, N=60, Completed,
Our findings support the future safe use of classic psychedelics in assisted psychotherapy in patients with life-threatening diseases where immune suppression and diminished immune function would be detrimental. Active, not recruiting --> Completed | Trial primary completion date: Dec 2022 --> Sep 2022
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: SERT-LSD: Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects (clinicaltrials.gov) - Oct 26, 2022
P1, N=24, Recruiting,
Ketanserin can effectively be used as a planned or rescue option to shorten and attenuate the LSD experience in humans in research and LSD-assisted therapy. Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> Apr 2024 | Initiation date: Mar 2022 --> Oct 2022 | Trial primary completion date: Sep 2023 --> Apr 2024
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Ketanserin reverses the acute effects of LSD in healthy subjects (Corner 1 (Hall X1) [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_1643;
The finding of this study is consistent with a competitive interaction of ketanserin and LSD at the 5-HT2A receptor. Ketanserin can effectively be used as a planned or as a rescue option to shorten or reduce an LSD experience in humans.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Ketanserin reverses the acute effects of LSD in healthy subjects (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_790;
The finding of this study is consistent with a competitive interaction of ketanserin and LSD at the 5-HT2A receptor. Ketanserin can effectively be used as a planned or as a rescue option to shorten or reduce an LSD experience in humans.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Journal: Dosing Psychedelics and MDMA. (Pubmed Central) - Aug 31, 2022
Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumatic stress disorder, among others...Furthermore, the so-called microdosing of psychedelics has recently gained popularity, and the first placebo-controlled studies of LSD have been published. This chapter discusses different aspects of psychedelic dosing, including pharmaceutical aspects, definitions and characteristics of different doses, including microdoses, aspects of personalized dosing, and non-pharmacological factors, that can influence the response to psychedelics.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion: LSD-MDMA: Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects (clinicaltrials.gov) - Aug 23, 2022
P1, N=24, Completed,
This chapter discusses different aspects of psychedelic dosing, including pharmaceutical aspects, definitions and characteristics of different doses, including microdoses, aspects of personalized dosing, and non-pharmacological factors, that can influence the response to psychedelics. Recruiting --> Completed
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Clinical, Journal: Safety pharmacology of acute LSD administration in healthy subjects. (Pubmed Central) - Jun 9, 2022
Recruiting --> Completed The single-dose administration of LSD is safe in regard to acute psychological and physical harm in healthy subjects in a controlled research setting.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment closed, Trial completion date, Trial primary completion date: LSD Therapy for Persons Suffering From Major Depression (clinicaltrials.gov) - May 25, 2022
P2, N=60, Active, not recruiting,
Further targeted research is warranted. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2022 | Trial primary completion date: Dec 2023 --> Dec 2022
- |||||||||| lysergic acid diethylamide (LSD) / Mindmed, University Hospital Basel
Clinical, Journal: LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking. (Pubmed Central) - May 6, 2022
Three phenomena of pattern break, disorganization and meaning seemed to fundamentally influence creative cognition and behaviour pointing to a shift of cognitive resources 'away from normal' and 'towards the new'. LSD-induced symbolic thinking might provide a tool to support treatment efficiency in psychedelic-assisted therapy.
- |||||||||| lysergic acid diethylamide (LSD) / Mindmed, University Hospital Basel
Review, Journal: Unconventional anxiety pharmacology in zebrafish: drugs beyond traditional anxiogenic and anxiolytic spectra. (Pubmed Central) - Feb 15, 2022
Emphasizing the growing utility of zebrafish models in CNS drug discovery, such unconventional anxiety pharmacology may provide important, evolutionarily relevant insights into complex regulation of anxiety in biological systems. Albeit seemingly complicating direct translation from zebrafish into clinical phenotypes, this knowledge may instead foster the development of novel CNS drugs, eventually facilitating innovative treatment of patients based on novel 'unconventional' targets identified in fish models.
- |||||||||| lysergic acid diethylamide (LSD) / Mindmed, University Hospital Basel
Clinical, Journal: A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. (Pubmed Central) - Jan 27, 2022
The present study provides evidence of a protracted analgesic effect of LSD at a dose that is low enough to avoid a psychedelic experience. The present data warrant further research into the analgesic effects of low doses of LSD in patient populations.
- |||||||||| lysergic acid diethylamide (LSD) / Mindmed, University Hospital Basel
Clinical, Journal: Acute subjective effects in LSD- and MDMA-assisted psychotherapy. (Pubmed Central) - Jan 27, 2022
Lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA) were used in psychotherapy in the 1960s-1980s, and are currently being re-investigated as treatments for several psychiatric disorders...LSD and MDMA are currently used medically in Switzerland mainly in patients with posttraumatic stress disorder and depression in group settings, producing similar acute responses as in research subjects. The data may serve as a basis for further controlled studies of substance-assisted psychotherapy.
|
